Latest / ESWI Airborne's Podcast / The Future of Immunological Medicine: Why Immune Responses Differ
Transcript
- 0:00ESWI Secretariat: Welcome to ESWI Airborne.
- 0:02ESWI Secretariat: In this series featuring our early career scientist community, we explore how the next generation is shaping the future of respiratory virus research.
- 0:10ESWI Secretariat: This series is made possible thanks to the kind support of CSL Seqirus and Sanofi Pasteur.
- 0:39Jane Barratt: I'm Dr.
- 0:40Jane Barratt: Jane Barratt.
- 0:41Jane Barratt: Today we are talking about the future of immunological medicine and one question that sits right at the heart of respiratory virus research.
- 0:50Jane Barratt: Why do people respond so differently to the same virus or the same vaccine?
- 0:56Jane Barratt: For a long time, immunology has been translated through averages.
- 1:01Jane Barratt: Average immune responses, average protection, average risk.
- 1:06Jane Barratt: But people are not averages.
- 1:08Jane Barratt: Immune responses are shaped by age, sex, immune history, underlying health, prior infection, vaccination history, genetics, and the wider biological context around immune system.
- 1:24Jane Barratt: Today I'm delighted to be joined by two early career scientists whose work helps us explore these from different but connected angles.
- 1:34Jane Barratt: First of all, it's my pleasure to introduce Dr.
- 1:38Jane Barratt: Alina Tscherne, is a postdoctoral researcher at the Infection Research Medical University of Vienna.
- 1:45Jane Barratt: Her work focuses on vaccine platforms and immune protection against emerging and respiratory viruses, including MVA-based vaccine candidates, mucosal COVID-19 vaccines, and correlates or protection for next generation influenza vaccines.
- 2:05Jane Barratt: So welcome, Alina.
- 2:07Jane Barratt: And our other expert researcher is Dr.
- 2:11Jane Barratt: Valentino D'Onofrio.
- 2:13Jane Barratt: He is a researcher at the Center for Vaccinology, Ghent University, and Ghent University Hospital.
- 2:20Jane Barratt: His work focuses on vaccine immunology, immunomonitoring, adjuvanted influenza vaccines, and the clinical interpretation of immune responses in infectious diseases.
- 2:34Jane Barratt: So I welcome both of you to this very important podcast.
- 2:39Jane Barratt: So hello to Valentino and hello to Alina.
- 2:42Valentino D'Onofrio: Hello.
- 2:42Alina Tscherne: Hello.
- 2:46Jane Barratt: Good to have you with us.
- 2:47Jane Barratt: So today during this podcast, we're going to move from vaccine-induced immune response to clinical outcomes to what this means for respiratory virus research.
- 2:58Jane Barratt: And Alina, I'm just going to turn to you initially because your work sits very closely to the moment where a vaccine first meets the immune system.
- 3:08Jane Barratt: So when you think about immune variability, what are the main factors that shape how someone really responds to a vaccine?
- 3:19Alina Tscherne: There are actually a lot of factors, and there are still factors which are not known, especially with these new vaccine platforms we have.
- 3:26Alina Tscherne: But factors that are known, for example, are intrinsic factors such as our age.
- 3:31Alina Tscherne: Also, there is a bias between females and males that vaccines are that the immune response induced by the vaccines is different.
- 3:40Alina Tscherne: Also, the genetic background plays a role.
- 3:42Alina Tscherne: And also comorbidities are known to play a role in inducing different immune responses.
- 3:49Alina Tscherne: And it's also actually something we are focusing at the moment.
- 3:53Alina Tscherne: But there are also other factors such as our behavior.
- 3:57Alina Tscherne: So, for example, smokers, or if you drink alcohol, also our sleeping behaviors, or also stress, for example, plays a role in shaping the immune response.
- 4:06Alina Tscherne: But also the vaccine vaccines itself play a role.
- 4:10Alina Tscherne: So we have these different platforms, mRNA vaccines, verbal vectors, and those are also inducing different immune responses.
- 4:19Alina Tscherne: So to give you examples.
- 4:24Jane Barratt: So I really want to talk to Valentino and come in with your perspectives.
- 4:30Jane Barratt: You know, from your perspective, what separates a protective immune response from one that is insufficient or misdirected or clinically harmful?
- 4:39Jane Barratt: And do you have any thoughts about these different gender perspectives in this?
- 4:45Valentino D'Onofrio: Yes, so from my perspective, I'm very much interested in the innate immune response.
- 4:49Valentino D'Onofrio: So of course I'm going to going to say and answer this question with the innate immune response, and especially inflammation is an important factor in driving a coordinated immune response or a harmful, clinically harmful immune response.
- 5:04Valentino D'Onofrio: So it's all about quality and the balance of the immune response.
- 5:09Valentino D'Onofrio: Of course, inflammation is needed when you encounter an antigen and it starts the whole immune response and it leads to antigen presentation, germinal center reactions, and eventually the adaptive response and your antibodies.
- 5:24Valentino D'Onofrio: But of course, if the pathogen is that powerful that your inflammation is going in overdrive, your inflammatory response starts to attack the tissues, the organs, and it creates this damage that then develops as disease and severe disease.
- 5:42Valentino D'Onofrio: So basically the quality is important, and we see differences in gender between the genders as well.
- 5:50Valentino D'Onofrio: So we know that women in general have a more coordinated, innate, and antiviral response.
- 5:56Valentino D'Onofrio: They are better at antigen presentation, which means that the response to infectious diseases less likely develops into a severe into severe disease compared to men.
- 6:09Jane Barratt: How do you measure quality, Valentina?
- 6:11Jane Barratt: You've measured quality a couple of times.
- 6:13Jane Barratt: How do you measure the quality response?
- 6:16Valentino D'Onofrio: So that's indeed very difficult to measure, but basically the introduction of novel omics techniques has given us a lot of tools to study a lot of different aspects of the immune response.
- 6:31Valentino D'Onofrio: So we don't only measure concentrations of cytokines, we can also measure gene expression, we can measure epigenetic changes, and then when we combine this, we can basically look at the whole system and we can see if the immune system is rewired towards a coordinated response, or is it or if it's going in overdrive.
- 6:52Jane Barratt: I'll come back to you about the the gender perspective because we don't really look at that when we we you know we talk to nights and and they're deliberating.
- 7:02Jane Barratt: There's there's uh you know, I think this is the first time I've really sort of talked with someone that has that perspective, so I'm going to come back to you.
- 7:09Jane Barratt: But Alina, you mentioned various vaccine platforms that you've worked on, including MVA-based candidates and mucosal vaccines.
- 7:19Jane Barratt: What have these platforms really taught us about the kind of response we should be trying to generate?
- 7:28Alina Tscherne: I mean, the overall goal for vaccine development is of course that we want to have a long-term immunity.
- 7:33Alina Tscherne: We want a protective immunity, and the immunity should be very balanced.
- 7:37Alina Tscherne: So not only focusing on humor immunity, but also on cellular immunity, so that we really get a good adaptive immune response by vaccinating.
- 7:46Alina Tscherne: And of course, we also want to have a broad reactive immunity, meaning that when we design the vaccines, we um in how should I say, ideally not only focus on one part of the vaccine, um, but also focusing on different parts of the vaccines.
- 8:01Alina Tscherne: So, for example, if we seen for SARS-CoV-2, where we had this immune evasion or this um escape mutants, um by by focusing on different parts of the virus, we can um how should I say that, we can um avoid uh that the immune response to the vaccine is decreased.
- 8:22Jane Barratt: So you're really you know looking at a number of different platforms to determine you know the degree of the immune response.
- 8:30Jane Barratt: Is that correct?
- 8:33Alina Tscherne: Well, I was mainly focusing on MVA vaccines, which is a good T cell in TSA besides humor immunity.
- 8:39Alina Tscherne: Um, but we did not really do a comparison between those platforms.
- 8:43Jane Barratt: Okay.
- 8:44Jane Barratt: Well, that's that's an interesting perspective.
- 8:46Jane Barratt: As we turn to Valentino now and talk with you about severe respiratory infections, you know, we often focus on the virus itself, obviously.
- 8:57Valentino D'Onofrio: But how much of the severe disease is actually driven by the host response from my perspective, I would say a lot of the uh the disease is driven by the host response.
- 9:10Valentino D'Onofrio: Of course, it depends on the pathogen.
- 9:12Valentino D'Onofrio: But if we take, for example, COVID-19, um, we know that um timing is very important.
- 9:18Valentino D'Onofrio: And we know that viral load or viral burden does not always correlate with the severe disease.
- 9:24Valentino D'Onofrio: Um, we know that from um studies with antiviral treatments.
- 9:29Valentino D'Onofrio: Um, so antiviral treatments are um basically only effective in the early stages of infection, so the first couple of days, but after that, they're not helping that much anymore, indicating that the inflammation, the immune response is going probably going in overdrive and is doing the damage.
- 9:45Valentino D'Onofrio: So it's the host that is overreacting rather than that the um the virus is doing damage.
- 9:51Valentino D'Onofrio: But of course, timing is is important, it's the pathogen um that sets everything in motion and um baseline factors such as comorbidities or age also influence this um this inflammatory response.
- 10:06Jane Barratt: Yeah, we we look at vaccination in such a simple way, don't we, as general public?
- 10:11Jane Barratt: But when you talked about timing, I immediately go to when vaccines are scheduled, you know, and COVID is a good example.
- 10:19Jane Barratt: You know, in some countries now we have you know two doses per year, and in other countries there aren't doses for certain populations.
- 10:28Jane Barratt: Would you like to just comment on that?
- 10:33Valentino D'Onofrio: Well, I think it's um it's um a timing, uh it's it's dependent on the population.
- 10:39Valentino D'Onofrio: Um so if we if we know that older adults are more susceptible to severe disease, it makes sense to give them more uh vaccine doses because a vaccine in Tiere gives you a coordinated immune response, a high quality response that is less likely to go in overdrive compared to an effect a response to an infection.
- 10:58Valentino D'Onofrio: Um so we can give that more often to older people to protect them from severe disease.
- 11:03Valentino D'Onofrio: But if you're not as susceptible to severe disease, it is less um important to vaccinate.
- 11:11Valentino D'Onofrio: So vaccinating the general population um might not be needed for COVID-19 all the time.
- 11:19Jane Barratt: It it really becomes very complicated when you've got complex comorbidities and age, etc., and gender, now we know.
- 11:27Jane Barratt: Um but Alina, we often talk about antibodies as the end point of a vaccine response, but your field seems to be asking deeper questions about correlates of protection.
- 11:40Jane Barratt: What should we be really measuring if we want to understand protection more fully?
- 11:46Alina Tscherne: Yeah, you're right.
- 11:47Alina Tscherne: Uh just focusing on antibodies alone might not be enough.
- 11:50Alina Tscherne: And the the problem is also that in preclinical studies, so when using animal models, there's more possibilities to test different aspects.
- 11:58Alina Tscherne: So not only human immunity, but also T cells, um, because you can actually euthanize the animals and get more, let's say, sample material to test, which is for clinical trials with human a bit more difficult.
- 12:10Alina Tscherne: Um, and also the sampling for humans itself is difficult.
- 12:14Alina Tscherne: So when talking about respiratory viruses and talking about mucosal antibody, uh mucosal um responses, it's it's easy to sample the nose with swaps.
- 12:24Alina Tscherne: But if you want to go deeper to look for lower and uh lower resp, uh how's it called lower airway samples, it becomes difficult because it's also quite painful if you do a lavage, for example.
- 12:34Alina Tscherne: So it's also a problem that you can sometimes not really test all the measure or the parameters you you measure, for example, preclinical trials.
- 12:41Alina Tscherne: And to really fully understand the protection of the vaccine, it's it's important to focus on you also on the different aspects.
- 12:48Alina Tscherne: So also when measuring um antibodies, there's different types of antibodies you can measure: IgG, IgA, also systemic IgG, mucosal IgG, so there are mucosal IgA.
- 13:01Alina Tscherne: So there are different um parameters which can actually be tested and would should really be recommended to test it to really get an idea what is the protective efficacy of the different vaccines, especially if it's a new vaccine.
- 13:14Jane Barratt: So there's certainly different ways of measuring that we should be paying attention to.
- 13:18Jane Barratt: So thank you.
- 13:20Jane Barratt: Um, Valentino, I'm going to continue the theme of at-risk populations and talk with you about older adults and your work on influenza vaccine adjuvants.
- 13:30Jane Barratt: So, what does that work tell us about improving vaccine responses in populations whose immune systems may respond differently?
- 13:40Jane Barratt: So the natural response of immunosinescence, but then the layering effect of chronic comorbidity.
- 13:46Jane Barratt: So, what do what does your work tell us about that?
- 13:51Valentino D'Onofrio: Um, so basically, um what it says is that we that we we need different platforms or different delivery systems for different at-risk populations.
- 14:00Valentino D'Onofrio: So, for older adults, um, we know that several aspects of the immune response are weakened.
- 14:06Valentino D'Onofrio: There's less antigen presentation, there's less toll-like receptor activation, T cells are becoming exhausted.
- 14:13Valentino D'Onofrio: And in the case for influenza, for example, we um we um it is recommended for very old older adults, so um 70 or 75 or older, and especially those in nursing homes that are very, very vulnerable to vaccinate them with an adjuvented vaccine or with a high dose antigen, uh high dose level of the antigen.
- 14:37Valentino D'Onofrio: Um, because we know that adjuvants are uh acting on those specific pathways that are weakened in those older adults.
- 14:44Valentino D'Onofrio: So adjuvants boost toll-like receptor activation, boost antigen presentation, can boost uh T cell immunity and does overcome or mitigate the effects of the immunosinescence that we see.
- 14:57Valentino D'Onofrio: So it's very effective in vaccinating older adults.
- 15:03Valentino D'Onofrio: But of course, adjuvants are also come along with higher reactogenicity, so there are more adverse events.
- 15:10Valentino D'Onofrio: So it might not be as useful in children, for example.
- 15:14Valentino D'Onofrio: Um so really the different platforms and the different delivery strategies need to be adapted for for every uh population.
- 15:22Jane Barratt: And and that's so true in older people or people with disabilities, you know, living in long-term care facilities.
- 15:31Jane Barratt: I think what we're trying to do there is really, you know, decrease the health system burden on the frontline professionals as well as maintain their functioners for as long as possible.
- 15:42Jane Barratt: So I think what you've said there is particularly important not only for researchers, but you know, people that are making policies.
- 15:50Jane Barratt: So what we've done in the first part of the podcast is really linked questions around how vaccines generate protection and how immune responses translate into protection.
- 16:02Jane Barratt: I want to now bring both of you together and look forward.
- 16:06Jane Barratt: So really the discussion is about what connects both of your work is the idea that immune responses are not fixed or uniformed and they're easily reduced to one measurement.
- 16:18Jane Barratt: So both Alina and Valentino, perhaps if you can respond to me around the question if immune responses vary this much between people, what does that mean for the future of vaccine design?
- 16:34Jane Barratt: And Alina, perhaps you can take that question from the perspective of a vaccine platform and Valentino from the immune monitoring and clinical perspective.
- 16:44Jane Barratt: So Alina, perhaps if you go first.
- 16:49Alina Tscherne: Yeah, it's uh it's quite a difficult question to answer, and it might depend also a bit on which virus we are looking at.
- 16:55Alina Tscherne: I mean, it has been seen in the past, for example, for smallpox, where everyone was vaccinated with the same vaccine that it worked.
- 17:01Alina Tscherne: We could eradicate smallpox with that.
- 17:04Alina Tscherne: Um, but um in speaking about future pandemics or future viruses for vaccine development, um, there's a trend towards a more maybe personalized um vaccine development.
- 17:17Alina Tscherne: Um, but therefore we would need a more detailed knowledge into individual immune profile, which is sometimes not known, which needs to be investigated, which might be cost effective.
- 17:26Alina Tscherne: So um, and that that's why it might not be suitable for now, but there is research going on on that.
- 17:33Alina Tscherne: Um yeah.
- 17:35Jane Barratt: You know, certainly what you're saying is that greater investment is required, you know, to actually answer this question about the future of vaccine design.
- 17:45Jane Barratt: From your perspective, Valentino, um, what what are your thoughts about immunomonitoring and clinical?
- 17:53Valentino D'Onofrio: Yeah, so I think for the for the future of vaccine design, again, we corresponding to my previous answer, we should embrace the diversity of platforms and delivery strategies that we already have and optimize those to the clinical, to the risk population and to the clinical outcome.
- 18:09Valentino D'Onofrio: Um, so uh again, adjuvants might be useful for older adults, but not so much for children.
- 18:14Valentino D'Onofrio: But also, what do we want to prevent?
- 18:17Valentino D'Onofrio: Um, do we want to prevent the infection or do we want to prevent severe disease?
- 18:22Valentino D'Onofrio: Um, for very old adults or at-risk adults, um, it might be enough to prevent infection uh the sorry the disease, because then it it reduces the burden of healthcare and hospitals.
- 18:36Valentino D'Onofrio: And if they don't get hospitalized, that's already well enough.
- 18:38Valentino D'Onofrio: But for children, you might want to go for strategies that um reduce or protect against infection, just so it doesn't get spread that easily and so that it doesn't dribble into other layers, layers of the population as well.
- 18:51Jane Barratt: You know, we've all experienced the pandemic, um, and we're still experiencing the consequences of this pandemic um throughout healthcare systems.
- 19:01Jane Barratt: And uh so I want you to put your future hat on and answer the question if a new respiratory virus emerged tomorrow, what early signal would most concern you?
- 19:16Jane Barratt: So, Alina, your thoughts about that?
- 19:20Jane Barratt: Because we hear in the in the background, in the noise, that there'll be another pandemic.
- 19:25Jane Barratt: Um, and I'm just curious as to what early signal would concern you most?
- 19:33Alina Tscherne: Yeah, so I also think there would be a new pandemic.
- 19:35Alina Tscherne: We don't know which one which virus will cause it, but there will most likely be one.
- 19:40Alina Tscherne: And I mean, in a compared to past pandemics, there were also already signs.
- 19:44Alina Tscherne: So if if we see an unexpected or unexplained pneumonia, respiratory illness in a population which is was previously not affected, like health, young population.
- 19:56Alina Tscherne: And also if we see an infection that it's really um human to human spreading, then I might be worried to see.
- 20:03Jane Barratt: Okay, well, I would certainly be worried.
- 20:05Jane Barratt: So thank you for that.
- 20:05Jane Barratt: Valentina, your thoughts about this?
- 20:08Valentino D'Onofrio: I think I would look at uh symptoms and how fast people get uh get ill and get severely ill.
- 20:15Valentino D'Onofrio: Um, because that means um, as we've seen with COVID, um uh this inflammation is getting disproportionate, people are getting a sepsis-like syndrome, they are getting hospitalized.
- 20:26Valentino D'Onofrio: Um so um that that completely to me changes the strategy in in vaccine design as well, because then the the initial priority might be reducing the healthcare burden, reducing hospitalizations, and reducing severe disease.
- 20:40Valentino D'Onofrio: Um, so then we need to study what is happening.
- 20:43Valentino D'Onofrio: Um, how is the pathology, what is the disease trajectory, who is going uh for who is staying with with asymptomatic disease and who is who is uh developing into severe disease.
- 20:54Jane Barratt: It's interesting, both of you, you know, as researchers, you've taught policy, and and I just want to commend you on that because you know, quite often, you know, researchers kind of stay in their research kind of territory, but both of you are really talked about you know the evidence that you're creating and how that can inform policy.
- 21:16Jane Barratt: But I want to come to one of the last questions, and that is what is the biggest gap today between immunology research and real-world application?
- 21:26Jane Barratt: And I'll I'll come back to you, Valentino, first.
- 21:29Jane Barratt: So, how do you see the gaps today?
- 21:34Valentino D'Onofrio: Um, to me, I think um the diversity and the variability is still a big gap.
- 21:39Valentino D'Onofrio: Um, so often, and we we've talked about this briefly, often, age and comorbidities or gender are confounding factors that we we measure and we we record, but we try to factor them out in our models and in our in our data so that they're not that confounding.
- 21:55Valentino D'Onofrio: But I I'm not sure this is the right strategies.
- 21:58Valentino D'Onofrio: The variability that we see in humans.
- 21:59Valentino D'Onofrio: It's huge, it's enormous.
- 22:01Valentino D'Onofrio: So we should just try to embrace this, embrace this and try to understand this better rather than factor this out.
- 22:09Valentino D'Onofrio: I think in the long run it will leave us with more information.
- 22:15Jane Barratt: Look, I think that you're absolutely quite right.
- 22:17Jane Barratt: By factoring it out, we're actually compounding the problem of not understanding.
- 22:22Jane Barratt: So thank you.
- 22:23Jane Barratt: Alina, your thought?
- 22:26Alina Tscherne: Yeah, what I see as a problem is that often in preclinical models we see positive results.
- 22:31Alina Tscherne: They look promising and then they fail in in real life or in clinical trials.
- 22:36Alina Tscherne: And there is really an improvement needed.
- 22:39Alina Tscherne: And also it's in, as I said, in real life patients, and also especially people with comorbidities are sometimes not that recognized or tested in clinical trials.
- 22:49Alina Tscherne: They're healthy individuals tested.
- 22:51Alina Tscherne: But when the vaccines are tested, then in elderly people or people that have other illnesses, they are not working.
- 22:58Alina Tscherne: So there is definitely improvement needed.
- 23:00Alina Tscherne: And also, um, as Valentino also mentioned, there is the variability of these platforms where we really need to further invest, develop, also focus maybe more on mucosal vaccines.
- 23:10Alina Tscherne: There is no research going on, but there's definitely room for improvement.
- 23:14Alina Tscherne: And also regulatory hurdles, hurdles of um vaccine um approval is still a problem, which takes too long, too many um issues.
- 23:24Alina Tscherne: So there's things that need to be improved on that.
- 23:28Jane Barratt: You know, you're really both talking about policy.
- 23:30Jane Barratt: So you might think about a career in policy after this.
- 23:34Jane Barratt: You know, you really are challenging, you know, the decision makers, you know, to look at vaccine development and various platforms, you know, through the lens of different populations, you know, and that's really cutting edge for today.
- 23:48Jane Barratt: Um, one rapid question before we we close to our final messages.
- 23:54Jane Barratt: What is one assumption in immunology that you believe we need to challenge?
- 24:00Jane Barratt: Valentino.
- 24:02Valentino D'Onofrio: I think that um that the assumption that we just should take vaccines when uh we are affected by it.
- 24:09Valentino D'Onofrio: I think if you have the opportunity, go get that influenza vaccine, go get all the vaccines that you can get, because in essence it's a training for your immune system.
- 24:17Valentino D'Onofrio: It's like going to the gym.
- 24:19Valentino D'Onofrio: You do it because you you try to stay healthy.
- 24:21Valentino D'Onofrio: And even uh recent evidence shows that there are more health benefits than only preventing infection or disease uh by vaccination.
- 24:30Jane Barratt: You know, I think that's a tag, training for your immune system.
- 24:34Jane Barratt: I think that we're going to use that going forward.
- 24:36Jane Barratt: So, Alina, one assumption in immunology we need to challenge.
- 24:41Alina Tscherne: Yeah, Valentina already took uh the thing I wanted to say, so I can completely agree what Valentina has said.
- 24:48Jane Barratt: Good.
- 24:48Jane Barratt: Well, I think that's a that's a um we we've agreed there's consensus.
- 24:53Jane Barratt: So as we come to uh the close of this podcast, which I've really enjoyed talking with both of you, what is your final message to the audience today?
- 25:04Jane Barratt: So, Alina, we'll start with you and uh finish off with Valentino.
- 25:09Alina Tscherne: Okay.
- 25:09Alina Tscherne: Um just to make it short, so vaccines are important.
- 25:14Alina Tscherne: And uh, if you're interested in vaccines, uh there are a lot of research groups who are working on that topic.
- 25:19Alina Tscherne: So join, um, work on that.
- 25:22Alina Tscherne: There will be a new pandemic, and maybe you can contribute uh to a vaccine for the next pandemic virus.
- 25:29Jane Barratt: And that's really a call out to all of the ESWI audience and their networks as well.
- 25:35Jane Barratt: So thank you.
- 25:36Jane Barratt: Valentino.
- 25:38Valentino D'Onofrio: Yes, so as for all aspects of society, I think also in vaccinology and immunology, we need to embrace diversity.
- 25:46Valentino D'Onofrio: So we don't need to leave or go away from diversity, equity, inclusion is initiatives.
- 25:51Valentino D'Onofrio: We need to embrace it.
- 25:52Valentino D'Onofrio: We need to embrace and understand variability.
- 25:55Valentino D'Onofrio: Um and yeah, just work with it.
- 25:58Valentino D'Onofrio: Everyone is unique and that is beautiful.
- 26:01Jane Barratt: So make that central to the work that we do and who we are.
- 26:06Jane Barratt: So today's discussion makes one thing very clear to me.
- 26:10Jane Barratt: The future of immunological medicine will not be built on averages, it will be built on understanding variation across biology, across age, across sex, immune history, across clinical risk, and across populations.
- 26:27Jane Barratt: And we've touched on all of those in our discussions today.
- 26:31Jane Barratt: That is not a narrow scientific point.
- 26:35Jane Barratt: It's really central to whether vaccines work well in people who need the most.
- 26:41Jane Barratt: And it's central to how we interpret severe disease.
- 26:45Jane Barratt: And lastly, it is central to how we prepare for the respiratory virus threats still ahead.
- 26:52Jane Barratt: My sincere thanks to Dr.
- 26:55Jane Barratt: Alina Tscherne and Dr.
- 26:57Jane Barratt: Valentino D'Onofrio for joining us today, and thank you to our audience for listening to this Eswee Airborne.
- 27:11ESWI Secretariat: ESWI Airborne is brought to you by ESWI, the European Scientific Working Group on Influenza and other acute respiratory viruses.
- 27:19ESWI Secretariat: These episodes would not be possible without the team's efforts, and I would like to extend special thanks to our ESWI Secretariat, our technical and IT teams, our arts team, and our host.
- 27:30ESWI Secretariat: The podcasts are recorded virtually, and we thank our guests for their participation in this inspiring and educational series.
- 27:39ESWI Secretariat: Talks are adapted to a global audience and are intended as recommendations and guiding principles.
- 27:46ESWI Secretariat: For any specific medical questions you may have, these should be addressed to your local general practitioner.
- 27:52ESWI Secretariat: Many thanks to our sponsoring partners, and thank you for listening.